Abbott Laboratories
- Open
- 109.32
- Day high
- 112.20
- Day low
- 109.00
- Prev close
- 108.97
- Volume
- 8.4M
- Mkt cap
- $191.2B
- P/E (TTM)
- 35.5
- EPS (TTM)
- $3.11
- P/B
- 3.7
- P/S
- 4.1
- Yield
- 2.24%
- Per share
- $2.48
- ▼Insiders net selling -$46.7M over the last 3 months (1 open-market buy, 3 sales)
- 🏛Institutions reducing (13F)
Abbott Laboratories (ABT) is a Healthcare company listed on NYSE. The stock is down 15% over the past year. Over the trailing 3 months, insiders filed 1 open-market buy and 3 sales (SEC Form 4). Drillr has 2 published research articles covering ABT.
Abbott Laboratories (ABT) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 11 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
ABT earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jul 16, 2026 | $1.28 | $1.31 | +2.2% | $12.6B | +0.8% |
| Apr 16, 2026 | $1.14 | $1.15 | +0.8% | $11.2B | +1.5% |
| Jan 22, 2026 | $1.50 | $1.50 | +0.0% | $11.5B | -2.8% |
| Oct 15, 2025 | $1.30 | $1.30 | -0.1% | $11.4B | -0.1% |
| Jul 17, 2025 | $1.26 | $1.26 | +0.0% | $11.1B | +0.5% |
| Apr 16, 2025 | $1.07 | $1.09 | +2.0% | $10.4B | -0.5% |
| Jan 22, 2025 | $1.34 | $1.34 | +0.1% | $11.0B | -0.3% |
| Oct 16, 2024 | $1.20 | $1.21 | +0.8% | $10.6B | +0.9% |
| Jul 18, 2024 | $1.10 | $1.14 | +3.8% | $10.4B | +0.4% |
| Apr 17, 2024 | $0.95 | $0.98 | +2.8% | $10.0B | +1.3% |
| Jan 24, 2024 | $1.18 | $1.19 | +0.7% | $10.2B | +1.2% |
| Oct 18, 2023 | $1.09 | $1.14 | +4.1% | $10.1B | +5.7% |
ABT insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 27, 2026 | Ford Robert Bdirector, officer: CHAIRMAN AND CEO | Option | 246,963 | $59.94 |
| Aug 27, 2026 | Ford Robert Bdirector, officer: CHAIRMAN AND CEO | Sell | 218,535 | $115.57 |
| Aug 27, 2026 | Ford Robert Bdirector, officer: CHAIRMAN AND CEO | Sell | 180,297 | $116.19 |
| Aug 27, 2026 | Ford Robert Bdirector, officer: CHAIRMAN AND CEO | Option | 151,869 | $44.40 |
| Aug 13, 2026 | Morrone Louis H.officer: EXECUTIVE VICE PRESIDENT | Sell | 5,850 | $109.83 |
| Jul 1, 2026 | Conroy Kevin Tdirector | Grant | 231 | — |
| Jul 1, 2026 | Ahuja Nitadirector | Grant | 347 | — |
| Jul 1, 2026 | Gonzalez Patricia Paoladirector | Grant | 363 | — |
| Jul 1, 2026 | Roman Michael Fdirector | Grant | 416 | — |
| Jul 1, 2026 | Stratton John Gdirector | Grant | 432 | — |
| Jul 1, 2026 | Morrone Louis H.officer: EXECUTIVE VICE PRESIDENT | Tax | 269 | $92.71 |
| Jun 29, 2026 | Cushman Elizabeth C.officer: EVP, GC AND SECRETARY | Tax | 560 | $94.12 |
| Jun 18, 2026 | Stratton John Gdirector | Buy | 2,000 | $86.82 |
| Apr 28, 2026 | McKinstry Nancydirector | Grant | 2,286 | — |
| Apr 28, 2026 | Gonzalez Patricia Paoladirector | Grant | 2,286 | — |
Source: ABT SEC Form 4 filings, latest Aug 27, 2026. For informational purposes only — not investment advice.
See the full ABT insider & 13F page →ABT research & analysis
[ABT] Abbott Thesis 2026: FreeStyle Libre Compounds Beyond Diabetes as Lingo Tests Consumer Wellness Category
Abbott FY2025 revenue ~$43B (+5-7% ex-COVID) with adj. operating margin ~22.5% and adj. EPS ~$5.20. FreeStyle Libre CGM franchise reached ~$7.5B (~6.5M users globally, +18-22% growth) — largest single growth driver. COVID test revenue wound down to ~$1B (from $7B FY2021 peak). Medical Devices segment ($19B at 30% margin) generates ~60% of consolidated operating income on 45% of revenue. Nutrition segment recovering from FY2022 Similac Sturgis Cronobacter contamination crisis. FY2026 thesis: Libre revenue toward $9-9.5B (Type 2 non-insulin expansion + Lingo consumer wellness launch); structural heart (MitraClip + TriClip) sustained growth; Diagnostics core lab + molecular stabilizing post-COVID; key risks: Dexcom G8 launch FY2026 with extended wear claims competing for Type 2 patients, Lingo consumer adoption uncertainty, Diagnostics organic growth recovery pace.
Non-Colonoscopy Colorectal Cancer Screening Gains Payer Coverage
Labcorp and Guardant Health each cleared ACS guidelines and national payer coverage for non-colonoscopy colorectal screening; Guardant raised guidance to $218-230M.
DGXGHLH
Abbott Laboratories company profile
Overview
Abbott Laboratories (NYSE:ABT) is a diversified healthcare company founded in 1888 and headquartered in North Chicago, Illinois. Originally established as a pharmaceutical company by Dr. Wallace Calvin Abbott, the company has evolved over more than 135 years into one of the world's largest healthcare corporations. Abbott operates across four major business segments: Medical Devices, Diagnostics, Nutritional Products, and Established Pharmaceutical Products, serving patients and healthcare providers in over 160 countries worldwide.
Business
Abbott Laboratories operates as a diversified healthcare company across four primary business segments, each addressing different aspects of human health and medical care. Medical Devices represents Abbott's largest and fastest-growing segment, generating approximately 40% of total revenue. This division develops and manufactures sophisticated medical technologies including continuous glucose monitoring systems (primarily the FreeStyle Libre platform for diabetes management), cardiovascular devices for treating heart conditions, electrophysiology equipment for diagnosing and treating irregular heart rhythms, and neuromodulation devices for managing chronic pain and movement disorders. The FreeStyle Libre continuous glucose monitoring system has become a cornerstone product, allowing diabetic patients to monitor their blood sugar levels without traditional finger-stick testing. Diagnostics accounts for roughly 25% of revenue and encompasses laboratory testing systems, molecular diagnostics, point-of-care testing devices, and rapid diagnostic tests. This segment provides the tools and technologies that hospitals, laboratories, and healthcare providers use to diagnose diseases, monitor patient health, and guide treatment decisions. Products range from large automated laboratory systems that process thousands of tests daily to portable devices that deliver results in minutes at the patient's bedside. Nutritional Products comprises approximately 20% of revenue, offering specialized nutrition solutions for different life stages and health conditions. This includes pediatric nutrition products like infant formula and children's nutritional supplements, as well as adult nutrition products designed for specific health needs such as recovery from illness, managing diabetes, or supporting healthy aging. Established Pharmaceutical Products generates about 15% of revenue, focusing primarily on generic pharmaceuticals and branded medicines in emerging markets. This segment provides treatments for various conditions including gastrointestinal disorders, women's health issues, cardiovascular conditions, and infectious diseases, with a particular emphasis on markets outside the United States where Abbott has established strong distribution networks.
Revenue model
Abbott generates revenue through direct product sales across its four business segments, with different customer bases and payment mechanisms for each division. The Medical Devices segment sells sophisticated medical equipment and consumables primarily to hospitals, clinics, and healthcare providers through both direct sales forces and distributor networks. Revenue comes from initial device sales and ongoing consumable sales, creating a recurring revenue stream. For diabetes care products like FreeStyle Libre, patients typically purchase sensors through pharmacies with insurance coverage, while healthcare institutions purchase monitoring systems and supplies directly. Diagnostics operates on a combination of equipment placement and consumable sales, where Abbott often places diagnostic instruments at customer sites and generates ongoing revenue from test cartridges, reagents, and service contracts. Customers include hospital laboratories, independent clinical laboratories, blood banks, and physician offices that pay per test or through service agreements. Nutritional Products are sold through retail channels, healthcare providers, and direct-to-consumer platforms. Revenue comes from product sales to distributors, retailers, and end consumers, with pricing varying by geography and product category. Established Pharmaceuticals generates revenue through sales to distributors, pharmacies, and healthcare systems, primarily in emerging markets where Abbott has built strong commercial presence and regulatory relationships. Several factors influence Abbott's margins and profitability. Positive margin drivers include the company's shift toward higher-margin medical devices and diagnostics, operational efficiency improvements, economies of scale in manufacturing, and pricing power in innovative products like continuous glucose monitoring. The company's diversified geographic presence also provides natural currency hedging and access to faster-growing emerging markets. Margin pressures come from healthcare cost containment efforts, competitive pricing in generic pharmaceuticals, raw material cost inflation, regulatory compliance costs, and the need for continuous research and development investment. Additionally, foreign exchange fluctuations can impact international revenue when translated back to US dollars, and healthcare reimbursement changes can affect product adoption and pricing.
Competitive moat
Abbott maintains a moderately strong competitive moat built on several defensive characteristics, though the strength varies across its business segments. The company's primary moat stems from its diversified portfolio of essential healthcare products that benefit from high switching costs and regulatory barriers. In Medical Devices, Abbott has established strong positions in specialized markets like continuous glucose monitoring, where the FreeStyle Libre platform has achieved significant market penetration and user loyalty. Patients and healthcare providers are reluctant to switch monitoring systems due to familiarity, data continuity, and integration with treatment protocols. The company's cardiovascular devices also benefit from surgeon preference and hospital purchasing relationships that create sticky customer bases. Regulatory barriers provide additional protection, as Abbott's products require extensive clinical trials, FDA approvals, and ongoing compliance monitoring that create significant barriers to entry for new competitors. The company's established relationships with regulatory agencies worldwide and deep regulatory expertise provide advantages in bringing new products to market. Scale advantages in manufacturing, distribution, and R&D spending allow Abbott to invest in innovation while maintaining cost competitiveness. The company's global manufacturing network and established distribution channels create operational efficiencies that smaller competitors struggle to replicate. However, Abbott faces meaningful competitive threats from both established healthcare giants and emerging technology companies. In diabetes care, companies like Dexcom offer competing continuous glucose monitoring systems, while tech companies like Apple are exploring health monitoring capabilities. The diagnostics business faces competition from companies like Roche and Siemens, while the pharmaceutical segment operates in highly competitive generic drug markets with limited differentiation. The company's moat is moderately durable but requires continuous innovation and market execution to maintain competitive positions, particularly in rapidly evolving areas like digital health and personalized medicine.
Risks & safety
Abbott demonstrates a solid margin of safety with strong financial fundamentals and manageable risk factors. Liquidity and Solvency: • Cash and short-term investments: $7.6 billion as of Q4 2024 • Current ratio: 1.67, indicating adequate short-term liquidity • Debt-to-equity ratio: 0.32, representing conservative leverage • Strong operating cash flow generation: $8.6 billion in 2024 • Free cash flow: $6.4 billion in 2024, providing substantial financial flexibility Valuation Metrics: • Price-to-earnings ratio: 14.6x based on 2024 results, reasonable for a diversified healthcare company • EV/EBITDA: 18.8x, reflecting premium valuation but justified by growth profile • Price-to-book ratio: 4.1x, elevated but typical for asset-light healthcare businesses • Graham number suggests fair valuation relative to earnings and book value Other Considerations: • Diversified revenue streams across four business segments reduce concentration risk • Strong market positions in essential healthcare products provide revenue stability • Consistent dividend payments and share repurchase programs demonstrate capital allocation discipline • Regulatory and litigation risks exist, particularly related to infant formula lawsuits, but appear manageable given the company's financial resources and insurance coverage
Recent development
Over the past several years, Abbott has executed a strategic transformation focused on high-growth, high-margin medical technologies while maintaining its diversified healthcare portfolio. The company's most significant development has been the explosive growth of its FreeStyle Libre continuous glucose monitoring platform, which has evolved from a niche product to a multi-billion dollar franchise generating over $7 billion in annual sales. Abbott has expanded Libre's market reach beyond traditional type 1 diabetes patients to include type 2 diabetes patients and launched consumer-focused applications like Lingo for metabolic health monitoring in non-diabetic populations. In cardiovascular devices, Abbott has built a comprehensive structural heart portfolio through acquisitions and internal development, including the MitraClip for mitral valve repair, Navitor transcatheter aortic valve replacement system, and TriClip for tricuspid valve repair. The company has also advanced its electrophysiology capabilities with mapping systems and is preparing to launch pulsed field ablation technology. Strategic partnerships and connectivity initiatives have become increasingly important, with Abbott forming alliances with companies like Medtronic to integrate glucose monitoring with insulin delivery systems. The company has also invested heavily in digital health platforms and data analytics capabilities to enhance product value propositions. Abbott has pursued geographic expansion particularly in emerging markets through its Established Pharmaceuticals division, launching biosimilar products and expanding access to essential medicines. The company has also strengthened its nutritional products portfolio and manufacturing capabilities following the infant formula supply chain disruptions. Recent regulatory achievements include multiple product approvals across segments, with particular focus on next-generation medical devices that incorporate digital connectivity and advanced materials. The company continues to invest approximately 7% of revenue in research and development to maintain its innovation pipeline.
ABT company profile · for informational purposes only — not investment advice.
Track ABT with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free